GET DAILY SIGNALSActinium Pharmaceuticals (ATNM): Monitoring Advances in Targeted Radiotherapies
Key Takeaways
- Near-term data catalysts: First-in-human Phase 1 results for ATNM-400, the company's HER3-targeted radiotherapy, are progressing, with additional clinical milestones expected from late 2026 through 2027.
- Strategic positioning: Actinium is pioneering targeted radiotherapies, or "radioconjugates," that deliver radiation directly to cancer cells, spanning hematologic cancers and multiple solid-tumor indications.
- Industry tailwind: The radiopharmaceutical sector is benefiting from rising investment and a shift toward targeted, lower-toxicity cancer treatments, supporting demand for novel isotopes such as Actinium-225 (Ac-225).
- Analyst stance: Consensus ratings are predominantly Buy, with published 12-month price targets clustering between roughly $3 and $5, reflecting optimism tied to pipeline execution.
- Key sensitivities: As a clinical-stage biotech, the stock is highly sensitive to trial data, regulatory decisions, financing conditions, and compliance with NYSE American continued listing standards.
- Risks to watch: Clinical setbacks, dilution risk, manufacturing scale-up challenges, and the company's limited revenue base could alter the outlook.
- For more on this ticker, explore its Major News, Today's Price Move, Price Targets, and Earnings pages.
- You can also explore Trending AI Robots to see how automated strategies are scanning the market.
Strategic Positioning in the Radiopharmaceutical Space
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on targeted radiotherapies designed to improve outcomes for cancer patients with limited options. Its market positioning rests on a biology-driven approach that combines tumor biology, translational medicine, and radiochemistry to create antibody-radiation conjugates that aim to maximize therapeutic effect while minimizing damage to healthy tissue.
The company's pipeline is organized around several pillars. In solid tumors, ATNM-400 targets HER3 (human epidermal growth factor receptor 3), a protein distinct from PSMA (prostate-specific membrane antigen), giving it a differentiated angle in prostate cancer and pan-tumor development. Actimab-A, a CD33-targeted radiotherapy, serves as a backbone therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while also being explored to target immunosuppressive myeloid cells in solid tumors. Complementing these are Iomab-B and Iomab-ACT, targeted conditioning agents for bone marrow transplant and cell/gene therapies.
A structural advantage is the company's end-to-end radiopharmaceutical supply chain, including its proprietary cyclotron-based Ac-225 production technology and a cGMP (current Good Manufacturing Practice) manufacturing facility expected to be operational in the second half of 2026. This vertical integration could support supply reliability and cost efficiency as trials scale. However, the company's small revenue base and reliance on a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) underscore its dependence on clinical and partnership execution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Major Catalysts on the Horizon
Several upcoming developments could shape investor sentiment. The most significant is the continued clinical readout for ATNM-400, following early Phase 1 data showing HER3-specific tumor uptake and an absence of dose-limiting toxicities at the starting dose level. Additional dose-escalation data and pan-tumor preclinical results in lung, colorectal, and ovarian models could broaden the program's perceived addressable market.
For the hematology franchise, Actimab-A is advancing toward a Phase 2/3 trial in relapsed/refractory AML, with data from NCI-backed trials expected across 2026 and 2027. Regulatory and manufacturing milestones—including the newly added manufacturing source and amended Investigational New Drug (IND) application—are also notable, as they de-risk supply for broader studies.
On the analyst front, consensus sentiment remains constructive. According to third-party aggregators, the consensus rating ranges from "Moderate Buy" to "Strong Buy," with an average 12-month price target near $3.50 to $4.00 and a high estimate of $5.00. Recent actions include H.C. Wainwright reiterating a Buy rating and $4 target in early November 2026, and JonesTrading reiterating Buy with a $3 target in October 2026. A notable risk-related catalyst is the company's plan to regain compliance with NYSE American continued listing standards, extended through November 2027.
Industry and Macroeconomic Influences
The radiopharmaceutical industry is experiencing a period of expansion, driven by growing clinical validation of targeted radiotherapies and increased deal activity from large pharmaceutical companies seeking differentiated oncology assets. This environment could support partnership opportunities and financing for Actinium's pipeline, particularly for late-stage programs.
Interest rates and inflation remain relevant, though indirectly. As a clinical-stage company, Actinium's cost structure is dominated by research and development, and its access to capital depends on equity financing conditions. Higher rates can raise the cost of capital and pressure valuations of pre-revenue biotechs, while a more accommodative environment can ease funding. Geopolitical factors affecting medical isotope supply chains and regulatory climate around radiopharmaceuticals also matter, given the specialized handling and manufacturing required for alpha-emitters like Ac-225.
2026 Outlook and Longer-Term Themes
Looking toward 2026 and beyond, Actinium's trajectory hinges on converting a broad, differentiated pipeline into validated clinical milestones. The central long-term theme is ATNM-400's evolution into a potentially pan-tumor, non-PSMA radiotherapy franchise, with prostate, lung, and breast cancer representing multi-billion-dollar market opportunities if clinical data continue to support differentiation.
Cost structure and margin sustainability will depend on the ramp-up of internal cGMP manufacturing and the company's cyclotron-based isotope production, which could lower supply costs and improve scalability. Strategic partnerships for late-stage hematology programs such as Actimab-A and Iomab-B remain a stated priority and could provide non-dilutive funding and global commercialization reach.
Competitive threats include larger radiopharmaceutical players and emerging PSMA-targeted competitors, making differentiation of the HER3 target a key watch item. Regulatory developments, particularly FDA (U.S. Food and Drug Administration) alignment on pivotal trial design, and the resolution of NYSE American listing compliance will also shape sentiment. While consensus price targets suggest meaningful upside relative to recent trading levels, these figures reflect external analyst expectations rather than a forecast, and the stock's outlook remains tied to binary clinical outcomes and financing capacity. From what I see, this is important because clinical execution will likely drive the next moves.
Exploring AI-Powered Market Insights
In my own analysis process, I frequently reference Tickeron’s Trend Prediction Engine to evaluate potential short-term directional trends for names like ATNM. This AI-driven tool provides searchable predictions, historical context, and alerts that help complement fundamental catalyst tracking with quantitative signals across various timeframes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ATNM in upward trend: 10-day moving average moved above 50-day moving average on October 20, 2026
The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +23.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 165 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATNM as a result. In 77 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for ATNM turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ATNM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (3.482). P/E Ratio (4.086) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers
Industry Biotechnology
Advertisement